Literature DB >> 17610016

Secular trends in the use, quality, and outcomes of gastrectomy for noncardia gastric cancer in the United States.

Anne Le1, David Berger, Melvin Lau, Hashem B El-Serag.   

Abstract

BACKGROUND: The overall survival with non-cardia gastric adenocarcinoma in the United States has remained poor and relatively unchanged over the past 2 decades. This brings into question the utilization and quality of gastrectomy and lymphadenectomy. We examined the trends, extent, and determinants of surgical treatment and the influence of gastrectomy and adequacy of lymphadenectomy (defined as collection of 15 or more lymph nodes) on non-cardia gastric cancer survival.
METHODS: Data from Surveillance, Epidemiology, and End Results (SEER) registries was used to identify patients with non-cardia adenocarcinoma diagnosed during 1983-2002. Logistic regression was used to examine determinants of gastric resection and adequacy of lymphadenectomy. Cox proportional hazard (PH) models were used to examine determinants of mortality risk for patients treated surgically. All models examined year of diagnosis, age, race, gender, geographic region, and cancer spread.
RESULTS: There were 16,846 patients with non-cardia gastric cancer of whom 10,534 (62.5%) underwent gastric resection. Approximately 77.9% with localized disease underwent resection. Resection for non-cardia gastric cancer declined 6% for all stages and 20% for local stages between 1983 and 2002. In multivariable models, gastrectomies were less likely to be performed between 1998-2002 (-37% compared to 1983-1987), for localized disease (-78% compared to regional disease), for patients older than 70 (-39% compared to patients younger than 40), and for patients from New Mexico (-45% compared to highest in Hawaii). Wide racial variability was also found (lowest for Whites [-54%] compared to Asians). Adequate LN sampling (15 or more LN) was recorded in only 25% overall and 20% of localized disease. Improvement in LN collection since 1997 has been modest, with only a 7% relative increase. The mortality risk of surgically treated non-cardia cancer patients has been unchanged for 15 years. Adequate lymphadenectomy was associated with a 19% decreased mortality risk in this group. Gender and racial differences in mortality risk were present (up to 13% higher in men compared to women and 22% higher in Whites compared Asians).
CONCLUSION: Gastrectomy for non-cardia gastric adenocarcinoma is underutilized, especially for localized disease. In the majority of operations for non-cardia gastric cancer, LN collection is inadequate. Racial and geographic variations with gastric resection and LN sampling are as significant as patient age and stage of the cancer. Disparities based on race and geographic region, as well as surgeon and facility factors need to be investigated and addressed to bring forth improvements in outcomes for non-cardia adenocarcinoma.

Entities:  

Mesh:

Year:  2007        PMID: 17610016     DOI: 10.1245/s10434-007-9386-8

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  18 in total

Review 1.  Location, size, and distance: criteria for quality in esophagogastroduodenos copy reporting for pre-operative gastric cancer evaluation.

Authors:  Nikila C Ravindran; Jovanka Vasilevska-Ristovska; Natalie G Coburn; Alyson Mahar; Yimeng Zhang; Nadia Gunraj; Rinku Sutradhar; Calvin H Law; Jill Tinmouth
Journal:  Surg Endosc       Date:  2014-01-23       Impact factor: 4.584

2.  Trends in the management of gastric cancer over a 32-year period: a French population-based study.

Authors:  Elodie Herbreteau; Valérie Jooste; Samia Hamza; Côme Lepage; Jean Faivre; Anne-Marie Bouvier
Journal:  Gastric Cancer       Date:  2014-02-01       Impact factor: 7.370

3.  Laparoscopy-assisted distal gastrectomy versus laparoscopy-assisted total gastrectomy with D2 lymph node dissection for middle-third advanced gastric cancer.

Authors:  Zhengyan Li; Gang Ji; Bin Bai; Deliang Yu; Yezhou Liu; Bo Lian; Qingchuan Zhao
Journal:  Surg Endosc       Date:  2017-11-02       Impact factor: 4.584

4.  Evaluating Dissemination of Adequate Lymphadenectomy for Gastric Cancer in the USA.

Authors:  Anthony M Villano; Alexander Zeymo; James McDermott; Andrew Crocker; Jay Zeck; Kitty S Chan; Nawar Shara; Sunnie Kim; Waddah B Al-Refaie
Journal:  J Gastrointest Surg       Date:  2019-02-20       Impact factor: 3.452

5.  Race and correlations between lymph node number and survival for patients with gastric cancer.

Authors:  Rebecca Nelson; Eun Bi Ko; Amanda Arrington; Wendy Lee; Jae Kim; Julio Garcia-Aguilar; Joseph Kim
Journal:  J Gastrointest Surg       Date:  2013-01-04       Impact factor: 3.452

6.  Time trends and disparities in lymphadenectomy for gastrointestinal cancer in the United States: a population-based analysis of 326,243 patients.

Authors:  A Dubecz; N Solymosi; M Schweigert; R J Stadlhuber; J H Peters; D Ofner; H J Stein
Journal:  J Gastrointest Surg       Date:  2013-01-24       Impact factor: 3.452

7.  Prognostic significance of signet ring gastric cancer.

Authors:  Sharven Taghavi; Senthil N Jayarajan; Adam Davey; Alliric I Willis
Journal:  J Clin Oncol       Date:  2012-08-27       Impact factor: 44.544

8.  Surgical treatment of gastric cancer in a community hospital in Brazil: who are we treating and how?

Authors:  Rachid Nagem; Lila G M F Bicalho; Laércio G Lourenço
Journal:  J Gastrointest Cancer       Date:  2013-12

9.  Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.

Authors:  Stephen R Smalley; Jacqueline K Benedetti; Daniel G Haller; Scott A Hundahl; Norman C Estes; Jaffer A Ajani; Leonard L Gunderson; Bryan Goldman; James A Martenson; J Milburn Jessup; Grant N Stemmermann; Charles D Blanke; John S Macdonald
Journal:  J Clin Oncol       Date:  2012-05-14       Impact factor: 44.544

10.  National Trends in Utilization of Endoscopic Ultrasound for Gastric Cancer: a SEER-Medicare Study.

Authors:  Ciara R Huntington; Kendall Walsh; Yimei Han; Jonathan Salo; Joshua Hill
Journal:  J Gastrointest Surg       Date:  2015-11-09       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.